AbbVie ABBV Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from AbbVie’s reported figures.
Based on trailing twelve months.
The official record: AbbVie’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about AbbVie's return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is AbbVie's return on equity?
- AbbVie (ABBV) reported return on equity of 89% in Q1 2025.
- How has AbbVie's return on equity changed year-over-year?
- AbbVie's return on equity increased by 58.0% year-over-year, from 56.3% to 89%.
- What is the long-term trend for AbbVie's return on equity?
- Over 3 years (2021 to 2024), AbbVie's return on equity has grown at a -8.3% compound annual growth rate (CAGR), from 81% to 62.5%.
- What does return on equity mean?
- How much profit the company earns on the money shareholders have invested.
- How do you interpret return on equity?
- Higher is better, but very high ROE can be manufactured by leverage — a thin equity base inflates the ratio. Read it next to debt-to-equity and ROIC to tell genuine returns from balance-sheet engineering.
- How does return on equity compare across companies?
- Comparable across peers, with the leverage caveat. Negative or near-zero equity makes ROE meaningless, so it is suppressed there.